Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist (LY3437943) — investigational; not FDA-approved.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. Retatrutide (developmental code LY3437943) is a triple agonist of the GIP, GLP-1, and glucagon receptors. PubChem CID 171390338; formula C221H342N46O68 / MW ~4731; CAS 2381089-83-2. Badge the named object as retatrutide / LY3437943 with that CID and CAS — do not print PubChem Title “Triple G” alone, and do not badge impurity CID 178245959 or sodium-salt CIDs (e.g. 171934787) as the parent. No approved US/EU indication in this drawer. Off-label does not apply. There is no label to be off of. It is not semaglutide, tirzepatide, liraglutide, mazdutide, or survodutide. A dual GIP/GLP-1 paper or a dual GLP-1/glucagon paper is a different object.
Bottom line
PubMed holds a discovery-to-proof-of-concept report, phase 2 obesity and type 2 diabetes programs, and a phase 2a metabolic dysfunction–associated steatotic liver disease (MASLD) trial. Those are investigational human objects. They are not a labeled obesity, diabetes, or liver indication. Secondary reviews and meta-analyses summarize trial signals; they do not create a label.
Papers
Investigational — discovery / early human
PMID 35985340 — Coskun 2022
Tested: discovery pharmacology and early clinical proof of concept for LY3437943 (retatrutide) as a triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.
Does not show: a confirmatory phase 3 labeled claim, or equivalence to tirzepatide or semaglutide.
Investigational — obesity (phase 2)
PMID 37366315 — Jastreboff 2023
Tested: once-weekly injectable retatrutide versus placebo for body weight in adults with obesity (phase 2).
Does not show: a labeled obesity indication, a type 2 diabetes primary claim (see Rosenstock), or a different incretin product.
Investigational — type 2 diabetes (phase 2)
PMID 37385280 — Rosenstock 2023
Tested: once-weekly injectable retatrutide versus placebo and versus an active dulaglutide control for glycemic and weight endpoints in people with type 2 diabetes (phase 2).
Does not show: a labeled T2D indication, an obesity-without-diabetes result (that is Jastreboff), or that dulaglutide and retatrutide are interchangeable objects.
Investigational — MASLD (phase 2a)
PMID 38858523 — Sanyal 2024
Tested: once-weekly injectable retatrutide versus placebo for liver-fat and related metabolic endpoints in metabolic dysfunction–associated steatotic liver disease (randomized phase 2a).
Does not show: a labeled MASH/MASLD indication, or a substitute for the obesity or T2D phase 2 objects above.
Secondary synthesis (not primary efficacy)
PMID 40728138 — Misra 2025
Tested: systematic review of clinical trials of retatrutide for obesity.
Does not show: a new randomized trial; synthesis only.
PMID 38976545 — Ayesh 2024
Tested: meta-analysis comparing retatrutide trial arms to placebo and to dulaglutide for weight and diabetes-management endpoints as reported in included trials.
Does not show: a head-to-head labeled claim, or identity between retatrutide and dulaglutide.
PMID 37947489 — Doggrell 2023
Tested: expert commentary on retatrutide as an investigational obesity (and type 2 diabetes) candidate.
Does not show: primary phase 3 efficacy tables, or an approved indication.
What is not established
An approved obesity, type 2 diabetes, or MASLD/MASH indication in this drawer’s labeled-jurisdiction framing. Phase 3 confirmatory results as a substitute for the phase 2 objects above. Interchangeability with semaglutide, tirzepatide, liraglutide, mazdutide, or survodutide. A non-trial preparation is not the LY3437943 trial material.
Selected sources
35985340 37366315 37385280 38858523 40728138 38976545 37947489
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.